Résultats de l’essai clinique de phase III publiés ! L’équipe de Li Jianyong et Qiu Lugui a publié un article sur STTT démontrant la supériorité significative de l’orélabrutinib par rapport à la chimio-immunothérapie en traitement de première ligne de la leucémie lymphoïde chronique/lymphome lymphocytaire de petite taille. – qq.com
三期临床试验结果发布！李建勇/邱录贵团队STTT发文奥布替尼一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤显著优于化学免疫 qq.com
该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。
Questions frequentes
Which products are related to this article?
No strongly related product has been identified yet. The match updates automatically when the article or catalog changes.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
